Catalent Introduces New Corporate Brand to Champion “Missions That Matter” Across Global Healthcare

29 October 2025 | Wednesday | News

New identity reflects Catalent’s unparalleled service, patient-first focus, and best-in-class capabilities across pharma, biotech, and consumer health sectors.

  • Reflects Catalent’s unparalleled service and best-in-class capabilities across the pharmaceutical, biotech and consumer health categories
  • Reinforces Catalent’s position as a trusted partner in achieving Patient First outcomes

“At Catalent, we believe that every medicine, therapy and product we help develop, manufacture and deliver exemplifies our commitment to put patients first in everything we do,” said Alessandro Maselli, President and Chief Executive Officer. “This new brand and simplified approach speak not only to who we are today, but to the impact we have on global health, working side-by-side with our customers to achieve their goals and transform lives around the world.”

Catalent’s new brand comes at a pivotal time, as the company continues to build momentum and expand its global impact following its transition to private ownership under Novo Holdings in December of 2024. With the recent announcement of its new global headquarters in Tampa, Fla., Catalent anchors its operations across more than 40 sites worldwide, reinforcing Catalent’s global reach and readiness to meet the demands of an increasingly complex global healthcare ecosystem.

“Our customers count on us to help drive their efforts to make a difference in people’s lives,” said Trish Hunt, Group Vice President and Chief Marketing Officer. “Our new branding reflects exactly who we are and how we deliver: a company that puts patients first, provides tailored solutions with unparalleled service and champions every customer’s mission as if it were our own. It’s a bold step forward that aligns our identity with the experience that sets Catalent apart.”

Over the past decade, Catalent has supported the development and manufacture of products representing half of all FDA approvals. The company produces over 60 billion doses per year and has over 1,000 active development programs at any given time. This scale and expertise enables Catalent to meet the unique and evolving needs of the healthcare industry. Catalent has deep partnerships with customers of all sizes, from small or virtual organizations to large global companies. The company scales its approach according to what its customers need for their program to be a success.

The new branding is being launched today at CPHI Frankfurt and SupplySide Global, as well as on Catalent’s website (www.catalent.com) and social media channels and through updated marketing materials. The company’s global sites will transition to the new branding and structure over the coming months while maintaining uninterrupted service to customers.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close